|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Can Yücel Karabay
Dr. Muzaffer Kahyaoğlu
Contributors
Dr. Ahmet Caner Canpolat
Dr. Aysu Oktay
Dr. Hadi Verdiyev
Dr. Kemal Göçer
Dr. Mehmet Altunova
Dr. Mehmet Murat Yiğitbaşı
Dr. Merve Kapçık
Dr. Muhammed Ali Söyler
Dr. Muhammet Ali Ekiz
Dr. Mustafa Yenerçağ
Dr. Mustafa Yılmaz
Dr. Özkan Karaca
Dr. Ramazan Furkan Demirkıran
Dr. Seda Kurat Güldoğmuş
Dr. Sefa Sarı
Dr. Selim Süleyman Sert
Dr. Serkan Bulguroğlu
Dr. Ülkü Nur Koç
Dr. Yücel Kanal
|
| |
|
|
|
TEER for moderate to severe or severe functional mitral regurgitation: DRAGONFLY-FMR – China Pivotal StudyTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - TEER for moderate to severe or severe functional mitral regurgitation: DRAGONFLY-FMR – China Pivotal Study (Dr. Merve Kapçık)Prepared by: Dr. Merve Kapçık
Study Title: TEER for moderate to severe or severe functional mitral regurgitation: DRAGONFLY-FMR – China Pivotal Study
Presented at: EuroPCR 2025
Link: pcronline.com
Introduction:
Functional mitral regurgitation (FMR) worsens outcomes in heart failure. The DragonFly Valve Repair system offers a non-surgical solution.
Objective:
Evaluate 1-year safety and efficacy of DragonFly in symptomatic FMR patients despite guideline-directed medical therapy (GDMT).
Methods:
Prospective, multicenter, single-arm study in China
N=120 patients (MR ≥3+, NYHA ≥II)
Primary endpoint: all-cause death + first HF hospitalization at 12 months
Follow-up: discharge, 30d, 6M, 12M, up to 5Y
Results:
Mean age: 65.2 ± 10; female: 44.2%
NYHA III/IV: 63.3%; prior HF hospitalization: 83.6%
MR ≤2+: 97.2% at 12 months
Composite endpoint (death + HFH): 16.7%
HFH reduced from 76.7% to 12.5%
NYHA I/II at 12 months: 96.3%
KCCQ improvement: +21.5 points; 6MWD ^36.9m
No device-related complications; 30-day MAE: 0.8%
Conclusion:
DragonFly showed high safety (MAE 0.8%) and efficacy (97.2% MR reduction), improving symptoms and quality of life with reduced HF hospitalizations.
Comment:
DragonFly is a promising transcatheter option for FMR. Further global trials, including a European pivotal study, are awaited.
|
